Drug Profile

KRM II 81

Alternative Names: KRM-II-81

Latest Information Update: 07 Dec 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Wisconsin at Milwaukee
Developer RespireRx Pharmaceuticals; University of Wisconsin at Milwaukee
Class Analgesics; Antiepileptic drugs; Anxiolytics; Small molecules
Mechanism of Action GABA A receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Epilepsy; Pain

Most Recent Events

05 Dec 2022 RespireRx Pharmaceuticals enters a collaboration with National Institute of Neurological Disorders and Stroke to develop KRM II 81 in Pain
05 Dec 2022 RespireRx Pharmaceuticals plans a clinical for KRM II 81 in Pain
17 May 2022 Pharmacodynamics and Adverse event data from preclinical study in pain were released by RespireRx Pharmaceuticals

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com